Improve cough strength using SpiroGym
- Trial ID
- NCT06481540
- Official Title
- Effect of the SpiroGym App on Voluntary Cough Strength in Parkinson's Disease
- Goal
- Improve cough strength using SpiroGym
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- General University Hospital, Prague
- Study Type
- INTERVENTIONAL
- Enrollment
- 60 participants
- Conditions
- Parkinson Disease, Voluntary Peak Cough Strength, mHealth
- Interventions
- Expiratory muscle strength training + SpiroGym application, Expiratory muscle strength training
Plain-Language Summary
Aiming to boost voluntary cough strength so people with Parkinson's can clear their airways better and lower the risk of choking or chest infections. The program uses expiratory muscle strength training, which exercises the muscles that drive a strong cough by breathing out against resistance, and the SpiroGym app guides, times, and tracks those training sessions to keep practice consistent. It is a non‑drug, at-home approach that is intended to be used alongside your usual Parkinson's medications, which should be on a stable dose. Looking for adults 40 to 80 years old with Parkinson's on stable dopaminergic therapy; people with other neurological diseases, significant cognitive impairment (MoCA <19), breathing disorders, recent smoking, or uncontrolled high blood pressure are excluded.
Locations
- General University Hospital, Prague, Czechia
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Expiratory muscle strength training + SpiroGym application. Aiming to boost voluntary cough strength so people with Parkinson's can clear their airways better and lower the risk of choking or chest infections. The program uses expiratory muscle strength training, which exercises the muscles that drive a strong cough by breathing out against resistance, and the SpiroGym app guides, times, and tracks those training sessions to keep practice consistent. It is a non‑drug, at-home approach that is intended to be used alongside your usual Parkinson's medications, which should be on a stable dose. Looking for adults 40 to 80 years old with Parkinson's on stable dopaminergic therapy; people with other neurological diseases, significant cognitive impairment (MoCA <19), breathing disorders, recent smoking, or uncontrolled high blood pressure are excluded.
- Who can participate?
- Participants must be between 40 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 4 months.